New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
11:20 EDTVNDAVanda shares attractive amid negative sentiment, says Piper Jaffray
Piper Jaffray believes the negative sentiment surrounding shares of Vanda Pharmaceuticals presents an excellent entry point into the name. Piper says Vanda has yet to ramp its physician education efforts regarding Hetlioz and that the dug has the potential to be a multi-hundred million dollar product. The firm reiterates an Overweight rating on Vanda with a $21 price target.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
07:47 EDTVNDAVanda receives positive CHMP opinion for Hetlioz for sleeping disorder in the EU
Subscribe for More Information
April 20, 2015
08:12 EDTVNDAVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
April 13, 2015
17:48 EDTVNDAVanda announces Feb. 29, 2016 trial date for Fanapt patent cases
Vanda Pharmaceuticals announced a February 29, 2016 trial date for two pending cases against Roxane Laboratories regarding Roxane's submission of an ANDA to obtain approval to make and sell generic Fanapt. The two cases have been consolidated by agreement of the parties and are scheduled to be tried together in a four-day bench trial beginning on February 29, 2016. In C.A. No. 14-757-GMS, Vanda is asserting U.S. Patent No. 8,586,610 ('610 patent), covering methods of treating schizophrenia by administering Fanapt to certain patients, while in C.A. No. 13-1973-GMS, Vanda is asserting the U.S. composition of matter patent for Fanapt, U.S. Patent No. RE39,198. Both patents are listed in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The '610 patent expires November 2027 and the RE'198 patent expires November 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use